{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:58:32Z","timestamp":1781067512088,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) remains a major global health concern, with high morbidity and mortality and limited long-term treatment success. Psychedelic therapy has re-emerged as a potential novel intervention for AUD, yet little is known about how affected individuals perceive such treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This mixed-method study explored attitudes and perceptions of psychedelic therapy among individuals with AUD participating in two non-psychedelic clinical trials (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009102) and from addiction outpatient services (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910). Quantitatively, 112 participants completed a four-item questionnaire assessing knowledge of psychedelic research, expectations of research promise, and willingness to participate in a psychedelic therapy trial, and, if willing, preferred setting (group therapy, individual therapy, or no preference). Binary logistic regression examined predictors of willingness to participate. Qualitatively, semi-structured interviews with 10 patients from addiction outpatient services were thematically analyzed to identify factors shaping attitudes toward psychedelic therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Quantitatively, 62.5% of participants were aware of psychedelic research and 64.3% were willing to participate in a psychedelic therapy trial. Willingness was significantly associated with higher expectations of research success (OR\u2009=\u20093.30,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; .001), but not with age or knowledge alone. Qualitatively, participants expressed a spectrum of attitudes with positive, neutral, and negative salience shaped by perceptions of therapeutic potential, fears of addiction or loss of control, personal and societal experiences with substance use, and media exposure. Expectation of benefit emerged as a central factor influencing openness to psychedelic therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with AUD already participating in clinical trials generally demonstrate awareness and conditional openness toward psychedelic therapy, primarily determined by their expectations of research promise. Limitations of this study include participation bias in the clinical trial sample as well as the lack of measurement of bias through prior psychedelic use. Nonetheless, thorough informed consent addressing expectations and misconceptions about risk and addiction potential remains crucial for ethically and effectively conducting future psychedelic clinical trials in AUD populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-026-07104-w","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:18:42Z","timestamp":1781065122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study"],"prefix":"10.1007","author":[{"given":"Julian","family":"Kirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brabeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gutwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alva","family":"L\u00fctt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tsamitros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Repantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"7104_CR1","unstructured":"Bachmeier R, Dyba J, Klein T (2025) FVS+-Katamnese des Entlassjahrgangs 2022: Effektivit\u00e4t der station\u00e4ren Suchtrehabilitation von Fachkliniken f\u00fcr Alkohol- und Medikamentenabh\u00e4ngige. SuchtAktuell \u2013 Zeitschrift Des Fachverbandes Sucht + E V 1(1):28\u201343. https:\/\/www.sucht.de\/wp-content\/uploads\/2025\/11\/FVS_Sucht-Aktuell_1_2025-Kat_AM_Bachmeier.pdf"},{"key":"7104_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 29:289\u2013299","journal-title":"J Psychopharmacol"},{"issue":"10","key":"7104_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O\u2019Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79(10):953\u2013962. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","journal-title":"JAMA Psychiatry"},{"key":"7104_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qualitative Res Psychol 3:77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa","journal-title":"Qualitative Res Psychol"},{"issue":"1","key":"7104_CR5","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","volume":"14","author":"JJ Breeksema","year":"2024","unstructured":"Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, Schoevers R (2024) Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep 14(1):2929","journal-title":"Sci Rep"},{"issue":"4","key":"7104_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1017\/S1092852922000888","volume":"28","author":"S Dodd","year":"2023","unstructured":"Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M (2023) Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectr 28(4):416\u2013426. https:\/\/doi.org\/10.1017\/S1092852922000888","journal-title":"CNS Spectr"},{"key":"7104_CR7","unstructured":"Dr\u00f6ge K (2024) noScribe. AI-powered Audio Transcription (Version 0.6) [Computer software]. https:\/\/github.com\/kaixxx\/noScribe"},{"key":"7104_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.drugalcdep.2016.08.625","volume":"168","author":"M-J Fleury","year":"2016","unstructured":"Fleury M-J, Djouini A, Hu\u1ef3nh C, Tremblay J, Ferland F, M\u00e9nard J-M, Belleville G (2016) Remission from substance use disorders: A systematic review and meta-analysis. Drug Alcohol Depend 168:293\u2013306. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.08.625","journal-title":"Drug Alcohol Depend"},{"key":"7104_CR9","doi-asserted-by":"publisher","unstructured":"Hallihan H, Abboud S, Lee S, Rospenda K, Srimoragot M, Fink A (2024) A qualitative exploration of young adults\u2019 perceptions of a new intervention for alcohol use disorder. Ann Med 55(2). https:\/\/doi.org\/10.1080\/07853890.2023.2295983","DOI":"10.1080\/07853890.2023.2295983"},{"issue":"5","key":"7104_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/02698811251319457","volume":"39","author":"ME Jensen","year":"2025","unstructured":"Jensen ME, Stenb\u00e6k DS, Messell CD, Poulsen ED, Varga TV, Fisher PM, Nielsen MKK, Johansen SS, Volkow ND, Knudsen GM, Fink-Jensen A (2025) Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study. J Psychopharmacol 39(5):463\u2013473. https:\/\/doi.org\/10.1177\/02698811251319457","journal-title":"J Psychopharmacol"},{"issue":"6","key":"7104_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol (Oxford England) 22(6):603\u2013620. https:\/\/doi.org\/10.1177\/0269881108093587","journal-title":"J Psychopharmacol (Oxford England)"},{"issue":"5","key":"7104_CR11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/acer.14598","volume":"45","author":"C Kilian","year":"2021","unstructured":"Kilian C, Manthey J, Carr S, Hanschmidt F, Rehm J, Speerforck S, Schomerus G (2021) Stigmatization of people with alcohol use disorders: an updated systematic review of population studies. Alcoholism: Clin Experimental Res 45(5):899\u2013911","journal-title":"Alcoholism: Clin Experimental Res"},{"issue":"6","key":"7104_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ajad.13461","volume":"32","author":"A Kim","year":"2023","unstructured":"Kim A, Suzuki J (2023) Addiction specialists\u2019 attitudes toward psychedelics: A national survey. Am J Addictions 32(6):606\u2013609. https:\/\/doi.org\/10.1111\/ajad.13461","journal-title":"Am J Addictions"},{"issue":"7","key":"7104_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen P-\u00d8 (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol (Oxford England) 26(7):994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253","journal-title":"J Psychopharmacol (Oxford England)"},{"issue":"9859","key":"7104_CR13","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","volume":"380","author":"SS Lim","year":"2012","unstructured":"Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, AlMazroa MA, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Ezzati M (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2224\u20132260. https:\/\/doi.org\/10.1016\/S0140-6736(12)61766-8","journal-title":"Lancet"},{"issue":"1","key":"7104_CR14","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1111\/inm.70010","volume":"34","author":"E Louie","year":"2025","unstructured":"Louie E, Towers E, Morse AR, Watt J, Bryant Z, Haber P, Morley K (2025) The acceptability of psychedelic-assisted therapy amongst mental health consumers: utilising the theory of planned behaviour. Int J Ment Health Nurs 34(1):e70010. https:\/\/doi.org\/10.1111\/inm.70010","journal-title":"Int J Ment Health Nurs"},{"key":"7104_CR20","doi-asserted-by":"publisher","unstructured":"Luquiens A, Belahda D, Graux C, Igounenc N, Serrand C, Rochefort P, Mura T, Sergent F (2025) Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. https:\/\/doi.org\/10.1111\/add.70152. Addiction","DOI":"10.1111\/add.70152"},{"issue":"10","key":"7104_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/00048674241261779","volume":"58","author":"Z Nadeem","year":"2024","unstructured":"Nadeem Z, Parker S, McGovern H, Oestreich LK (2024) Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. Australian New Z J Psychiatry 58(10):904\u2013913","journal-title":"Australian New Z J Psychiatry"},{"issue":"9752","key":"7104_CR16","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, [David J], King LA, Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376(9752):1558\u20131565. https:\/\/doi.org\/10.1016\/S0140-6736(10)61462-6","journal-title":"Lancet"},{"key":"7104_CR17","doi-asserted-by":"crossref","unstructured":"Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Marsden J (2025) Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. Addiction","DOI":"10.1111\/add.16762"},{"key":"7104_CR21","volume-title":"RStudio: Integrated Development Environment for R. Posit Software","author":"Posit","year":"2025","unstructured":"Posit (2025) RStudio: Integrated Development Environment for R. Posit Software. PBC, Boston, MA. URL. http:\/\/www.posit.co\/"},{"key":"7104_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001517","author":"S Prostko","year":"2026","unstructured":"Prostko S, Wu A, Maddams S, Szpak V, Rosenblum N, Hilt LM, Suzuki J (2026) Attitudes toward psychedelic treatments by individuals with histories of substance use or psychiatric disorders: A survey study. J Addict Med. https:\/\/doi.org\/10.1097\/ADM.0000000000001517","journal-title":"J Addict Med"},{"key":"7104_CR25","doi-asserted-by":"publisher","unstructured":"Rieser NM, Bitar R, Halm S, Rossgoderer C, Gubser LP, Th\u00e9venaz M, Kreis Y, von Rotz R, Nordt C, Visentini M, Moujaes F, Engeli EJ, Ort A, Seifritz E, Vollenweider FX, Herdener M, Preller KH (2025) Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine 82. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103149","DOI":"10.1016\/j.eclinm.2025.103149"},{"issue":"9","key":"7104_CR26","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/add.12231","volume":"108","author":"M Roerecke","year":"2013","unstructured":"Roerecke M, Rehm J (2013) Alcohol use disorders and mortality: A systematic review and meta-analysis. Addiction 108(9):1562\u20131578. https:\/\/doi.org\/10.1111\/add.12231","journal-title":"Addiction"},{"issue":"2","key":"7104_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1556\/2054.2023.00264","volume":"7","author":"BM Ross","year":"2023","unstructured":"Ross BM, Neill JT (2023) Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy. J Psychedelic Stud 7(2):114\u2013118. https:\/\/doi.org\/10.1556\/2054.2023.00264","journal-title":"J Psychedelic Stud"},{"key":"7104_CR28","doi-asserted-by":"publisher","unstructured":"Schwarzkopf L, Murawski M, Riemerschmid C (2025) Jahresstatistik 2023 der professionellen Suchthilfe. In Deutsche Hauptstelle f\u00fcr Suchtfragen e.V. (Ed.), DHS Jahrbuch Sucht 2025 (pp. 193\u2013218). Deutsche Hauptstelle f\u00fcr Suchtfragen e. V. https:\/\/doi.org\/10.2440\/012-0027","DOI":"10.2440\/012-0027"},{"key":"7104_CR29","doi-asserted-by":"publisher","unstructured":"Simon R, Steinbrecher A, Falk J (2025) Rehabilitation substanzbezogener Abh\u00e4ngigkeitserkrankungen durch die Deutsche Rentenversicherung. In DHS Jahrbuch Sucht 2025 (pp. 219\u2013230). https:\/\/doi.org\/10.2440\/012-0028","DOI":"10.2440\/012-0028"},{"key":"7104_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.alcohol.2024.03.004","volume":"121","author":"R Skeva","year":"2024","unstructured":"Skeva R, Jay C, Pettifer S, Gregg L (2024) Alcohol treatment preferences and the acceptability of virtual reality therapy for treating alcohol misuse in adult drinkers. Alcohol 121:185\u2013192. https:\/\/doi.org\/10.1016\/j.alcohol.2024.03.004","journal-title":"Alcohol"},{"issue":"5","key":"7104_CR30","first-page":"512","volume":"9","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Heifets BD (2024) Expectancy effects in psychedelic trials. Biol Psychiatry: Cogn Neurosci Neuroimaging 9(5):512\u2013521","journal-title":"Biol Psychiatry: Cogn Neurosci Neuroimaging"},{"key":"7104_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13722-024-00517-y","volume":"19","author":"V Szpak","year":"2024","unstructured":"Szpak V, Kim A, Sager Z, Suzuki J (2024) Survey of Massachusetts peer recovery coaches\u2019 attitudes toward the use of psychedelics to treat substance use disorders. Addict Sci Clin Pract 19:86. https:\/\/doi.org\/10.1186\/s13722-024-00517-y","journal-title":"Addict Sci Clin Pract"},{"key":"7104_CR31","doi-asserted-by":"publisher","unstructured":"Tan SF, Briley P, NIHR MindTech HealthTech Research Centre (2025) Co-producing a survey on prospective acceptability of neuromodulation for mental health conditions with lived experience experts. BJPsych Open 11(Suppl 1). https:\/\/doi.org\/10.1192\/bjo.2025.10239","DOI":"10.1192\/bjo.2025.10239"},{"key":"7104_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/acer.70022","author":"DC Tomlinson","year":"2025","unstructured":"Tomlinson DC, Florimbio AR, Lee CA, Ilgen MA, Lin LA, Coughlin LN (2025) Patient perspectives on medications for alcohol use disorder: A systematic scoping review. Alcohol Clin Experimental Res. https:\/\/doi.org\/10.1111\/acer.70022","journal-title":"Alcohol Clin Experimental Res"},{"key":"7104_CR38","unstructured":"VERBI Software (2025) MAXQDA (Version 24) [Computer software]. https:\/\/www.maxqda.com"},{"issue":"9904","key":"7104_CR33","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJL, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382(9904):1575\u20131586. https:\/\/doi.org\/10.1016\/S0140-6736(13)61611-6","journal-title":"Lancet"},{"issue":"2","key":"7104_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1556\/2054.01.2017.008","volume":"1","author":"JI Wildberger","year":"2017","unstructured":"Wildberger JI, John CN, Hallock RM (2017) Perceptions of the medicinal value of hallucinogenic drugs among college students. J Psychedelic Stud 1(2):50\u201354. https:\/\/doi.org\/10.1556\/2054.01.2017.008","journal-title":"J Psychedelic Stud"},{"key":"7104_CR34","unstructured":"World Health Organization (2024) Global status report on alcohol and health and treatment of substance use disorders. World Health Organization (15.10.2025). https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/32b161e9-5683-40f5-a1c3-1c92a76d5cda\/content"},{"issue":"2","key":"7104_CR36","doi-asserted-by":"publisher","first-page":"e21944","DOI":"10.7759\/cureus.21944","volume":"14","author":"S Ziff","year":"2022","unstructured":"Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR (2022) Analysis of psilocybin-assisted therapy in medicine. Narrative Rev Cureus 14(2):e21944. https:\/\/doi.org\/10.7759\/cureus.21944","journal-title":"Narrative Rev Cureus"},{"issue":"1","key":"7104_CR37","doi-asserted-by":"publisher","first-page":"18225","DOI":"10.1038\/s41598-022-23056-5","volume":"12","author":"MF \u017duljevi\u0107","year":"2022","unstructured":"\u017duljevi\u0107 MF, Buljan I, Leskur M, Kaliterna M, Hren D, Duplan\u010di\u0107 D (2022) Validation of a new instrument for assessing attitudes on psychedelics in the general population. Sci Rep 12(1):18225. https:\/\/doi.org\/10.1038\/s41598-022-23056-5","journal-title":"Sci Rep"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07104-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07104-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07104-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:18:47Z","timestamp":1781065127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07104-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":38,"alternative-id":["7104"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07104-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For ethical approval and informed consent within the clinical trials see the registrations (NCT06333457 and NCT06308484). The qualitative study was approved by the ethics commission of Charit\u00e9 Berlin (EA4\/176\/24), and all procedures adhered to the Declaration of Helsinki. All participants provided written informed consent, which outlined the voluntary and uncompensated nature of their participation, their right to withdraw at any time, and guarantees of confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Julian Kirsch, Christopher Poppe, Anne Beck, Anna Brabeck, Stefan Gutwinski, Alva L\u00fctt, Annika Rosenthal and Nikolaos Tsamitros have no conflicts of interest to disclose. The institution of Dimitris Repantis has received research support from MAPS Europe B.V., COMPASS Pathways plc., and Beckley Psytech ltd. DR is a founding member and honorary Board Chair of MAPS Deutschland, a Germany-based non-profit research and educational organization associated with MAPS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"A part of this study was embedded within two clinical trials. ID: NCT06333457 and NCT06308484.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}